Broad capabilities, established expertise

As one of the world’s most renowned companies for contract development and manufacturing, we are recognized for our reliable, high-quality service, our global capacity, our innovative technology platforms, and our extensive experience. In 2019 we provided manufacturing services for more than 300 commercial molecules and supported the development of more than 700 pre-clinical and clinical molecules in small and large molecules as well as supporting the launch of pioneering autologous cell therapies.


Success for us is when you, as our partner, are fully satisfied. We continuously improve and innovate to meet your expectations and improve your chances of business success. Our broad capabilities span across biologics, small molecules, bioconjugates, and cell and gene therapies. We manage projects from pre-clinical stage through to commercialization, and our expertise covers both drug substance and drug product.

Trending now

Cutting it short: Lonza on APIs
Manufacturing timelines for highly potent APIs (HPAPIs) are getting shorter due to faster approvals and improved compounds entering the pipeline. Jakob Bonde and Ryan Littich co-authored a byline to share insights about how pharma companies can establish robust drug substance and drug product procedures to meet these shorted timelines. With the right strategy and CDMO partner, emerging biotech companies can successfully navigate these deadlines while positioning themselves for a successful scale up.
Small Biotech Success
Discover a series of personal narratives from small biotechs who chose to partner with us
New Product Introduction Process for cGMP Manufacturing
Introducing our New Product Introduction (NPI) process for Cell & Gene Therapies manufacturing: a standardized, systematic approach to tech transfers, manufacturing and Pre-Approval Inspection readiness to reliably take your therapy to commercialization.
We believe that the best outcome – for you and for your patients – can only come as a result of a successful collaboration. Together, we can solve the next challenge and bring your next medicine to life.

In the news

We have a broad view on the industry, and a depth of experience in developing and manufacturing therapies. Our scientific teams focus on devising credible, game-changing solutions that create value for our customers today by delivering the medicines of tomorrow.

View press releases

Our global footprint

With 37 sites across three continents and 11,148 employees, we capitalize on our global footprint and have the flexibility to address regional and even local marketplace needs.

View our locations